Brachytherapy News and Research

RSS

Brachytherapy is a minimally invasive procedure that involves the use of radioactive seeds the size of rice grains. Brachytherapy, an out-patient procedure, usually takes 45 minutes to an hour to perform. Most patients can return to their normal activities within days. The success rates of prostate brachytherapy have compared favorably with success rates of radical prostatectomy and external beam radiation. In comparison studies, prostate brachytherapy has shown to have a favorable side effect profile when compared with other modalities. Clinical studies have shown that prostate brachytherapy has a cure rate of 94% for appropriately selected patients.

Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor Center

Saint Mary's and Sierra Neurosurgery Group have partnered to create the region's first Brain Tumor Center in an effort to speed up the time between diagnosis and treatment.

8 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

'Because Life is for Living' campaign launched to raise awareness about brachytherapy

Former England Rugby World Cup winner Matt Dawson today launched the 'Because Life is for Living' campaign to raise awareness about brachytherapy, a very precise and highly effective form of radiotherapy to treat cancer.

30 Mar 2010

Varian Medical Systems to showcase radiotherapy and radiosurgery solutions at medical events in Asia

Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy and radiosurgery, will showcase its technology at two medical events in Asia during the month of March:

18 Mar 2010

Watchful waiting is viable option for many men with low risk prostate cancer

Active surveillance, also referred to as watchful waiting, is a viable option for many men with low risk prostate cancer although the concept continues to cause distress and confusion. James L. Mohler, MD, of Roswell Park Cancer Institute and chair of the NCCN Guidelines Panel for Prostate Cancer, discussed the role of active surveillance as well as other treatment options recommended in the recently updated NCCN Guidelines™ for Prostate Cancer at the NCCN 15th Annual Conference.

18 Mar 2010

Varian Medical Systems chooses EasyLink as provider for hosted fax services

EasyLink Services International Corporation, a premier global provider of comprehensive messaging services and e-commerce solutions, announced today that Varian Medical Systems has selected EasyLink as its provider for hosted fax services for an initial three-year term.

16 Mar 2010

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Researchers in the US and Denmark have made a breakthrough in image-guided targeting of prostate tumors during arc radiotherapy treatments. In research partially supported by Varian Medical Systems, physicists at Stanford University (California, USA) and Aarhus University Hospital (Aarhus, Denmark) have devised a method for 'real-time' tracking of the prostate motion using Varian's On-Board Imager® that shows promise in paving the way for advanced clinical treatments.

4 Mar 2010

Varian Medical Systems wins 100th X-ray tube patent

Varian Medical Systems, Inc., a premier supplier of X-ray tubes and flat panel digital image detectors, announced it has been awarded a patent for improved shielding in X-ray tubes. It is the company's 100th X-ray tube patent from the United States Patent Office.

23 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

ASTRO leads the way to help physicians improve safety and reduce medical errors

The American Society for Radiation Oncology has committed to a six-point patient protection plan that will improve safety and quality and reduce the chances of medical errors, ASTRO Board Chairman Tim R. Williams, M.D., said today.

4 Feb 2010

IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).

28 Jan 2010

IsoRay expands market awareness program by joining www.StockProfile.com

IsoRay, Inc., announced today that they have expanded their market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.

23 Jan 2010

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc., announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

21 Jan 2010

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds.

13 Jan 2010

Thames Valley Cancer Network implements ARIA system for Medical Oncology

A chemotherapy software solution that enables patients to become more involved in managing their own care has been successfully rolled out across a network of hospitals in the UK. The Thames Valley Cancer Network has implemented Aria for Medical Oncology™ from Varian Medical Systems and already has more than 850 clinical staff routinely using the system.

12 Jan 2010

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably.

6 Jan 2010

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought, according to a study in the January 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

6 Jan 2010

U.S. market for urological devices to reach over $5.4 billion in 2016

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.

6 Jan 2010

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Four cancer patients became the first in Latin America to receive treatment using a fast form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending modern care to more patients. Doctors at Hope International Centro de Radioterapia of Guatemala are now treating four patients using RapidArc® radiotherapy technology from Varian Medical Systems, one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme--an aggressive type of brain tumor.

22 Dec 2009

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.

22 Dec 2009

Brachytherapy News and Research

Further Reading

Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor Center

Cancer research at Georgia Tech: Report

'Because Life is for Living' campaign launched to raise awareness about brachytherapy

Varian Medical Systems to showcase radiotherapy and radiosurgery solutions at medical events in Asia

Watchful waiting is viable option for many men with low risk prostate cancer

Varian Medical Systems chooses EasyLink as provider for hosted fax services

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Varian Medical Systems wins 100th X-ray tube patent

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

ASTRO leads the way to help physicians improve safety and reduce medical errors

IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

IsoRay expands market awareness program by joining www.StockProfile.com

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Thames Valley Cancer Network implements ARIA system for Medical Oncology

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

U.S. market for urological devices to reach over $5.4 billion in 2016

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News